Revance Therapeutics, Inc. (RVNC)
(Delayed Data from NSDQ)
$25.80 USD
-0.26 (-0.30%)
Updated Mar 3, 2021 04:00 PM ET
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 24.41% |
| 2 | Buy | 17.88% |
| 3 | Hold | 9.48% |
| 4 | Sell | 5.03% |
| 5 | Strong Sell | 1.87% |
| S&P | 500 | 10.70% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
3-Hold of 5 3
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
F Value F Growth D Momentum F VGM
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
View All Zacks #1 Ranked Stocks
Zacks News
Revance's (RVNC) DaxibotulinumtoxinA BLA Decision Delayed
by Zacks Equity Research
Revance (RVNC) announces a delay in the FDA decision on its BLA for DaxibotulinumtoxinA for Injection due to COVID-19.
BMYNegative Net Change ABBVNegative Net Change RVNCNegative Net Change VTRSNegative Net Change
biotechs medical
Is a Surprise Coming for Revance (RVNC) This Earnings Season?
by Zacks Equity Research
Revance (RVNC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
RVNCNegative Net Change
medical
Revance Therapeutics (RVNC) Surges: Stock Moves 5.5% Higher
by Zacks Equity Research
Revance Therapeutics (RVNC) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
RVNCNegative Net Change AKCAPositive Net Change
biotechs medical
AbbVie's (ABBV) sBLA for Botox Gets Acceptance From FDA
by Zacks Equity Research
AbbVie's (ABBV) sBLA for expanding the label of Botox for use in pediatric patients with neurogenic detrusor overactivity gets acceptance from the FDA.
LLYPositive Net Change AMGNNegative Net Change ABBVNegative Net Change RVNCNegative Net Change
pharmaceuticals
Revance's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Revance Therapeutics.
RVNCNegative Net Change
medical
How Revance (RVNC) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Revance (RVNC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
RVNCNegative Net Change
medical
Implied Volatility Surging for Revance Therapeutics (RVNC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Revance Therapeutics (RVNC) stock based on the movements in the options market lately.
RVNCNegative Net Change
biotechs
Will Revance Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Revance Therapeutics.
RVNCNegative Net Change
medical
Allergan (AGN) Shareholders Approve Acquisition by AbbVie
by Kinjel Shah
Allergan's (AGN) shareholders give green signal to its pending merger with AbbVie for a transaction value of nearly $63 billion.
ABBVNegative Net Change AGNPositive Net Change RVNCNegative Net Change EOLSNegative Net Change
pharmaceuticals
Will Revance Therapeutics (RVNC) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Revance (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RVNCNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
AbbVie (ABBV) Shares Down So Far This Year: Here's Why
by Zacks Equity Research
AbbVie's (ABBV) stock suffers a poor run on the bourses due to pipeline setbacks, Humira sales erosion in EU and its proposed offer to buy Allergan.
ABBVNegative Net Change AGNPositive Net Change RVNCNegative Net Change EOLSNegative Net Change
pharmaceuticals
Revance Therapeutics (RVNC) Jumps: Stock Rises 5.2%
by Zacks Equity Research
Revance Therapeutics (RVNC) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
RVNCNegative Net Change ACORNegative Net Change
biotechs
Will Revance Therapeutics (RVNC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Revance (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RVNCNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Allergan Stock Falls as FDA OK's Botox Rival for Frown Lines
by Zacks Equity Research
Allergan's (AGN) stock declines almost 4% after FDA approves Evolus' Jeuveau injection to treat frown lines, which can pose strong competition to Botox.
AGNPositive Net Change LLYPositive Net Change RVNCNegative Net Change EOLSNegative Net Change
pharmaceuticals
Revance Therapeutics (RVNC) Q3 Earnings Preview: What to Look Out For
by Zacks Equity Research
Revance (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RVNCNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Revance Therapeutics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Revance Therapeutics Sees Hammer Chart Pattern: Time to Buy?
RVNCNegative Net Change
3 Drug/Biotech Stocks Up More Than 10% This Week
by Zacks Equity Research
The drugs/biotech sector is down this week due to broader market pressure, except a few stocks.
AGNPositive Net Change RVNCNegative Net Change SCMPPositive Net Change VTGNNegative Net Change
3 Drug/Biotech Stocks Up More Than 10% This Week
by Zacks Equity Research
The drugs/biotech sector is down this week due to broader market pressure, except a few stocks.
AGNPositive Net Change RVNCNegative Net Change SCMPPositive Net Change VTGNNegative Net Change
Revance's Neuromodulator Injection Positive in Phase III
by Zacks Equity Research
Revance (RVNC) releases positive top-line data from two pivotal phase III trials, evaluating RT002 for reducing wrinkles between the brows. The studies meet both primary and secondary endpoints.
AGNPositive Net Change ACHNNegative Net Change RVNCNegative Net Change CORTNo Net Change